@prefix rdf: . @prefix ns1: . @prefix ns2: . ns1:DB01030 rdf:type ns2:Drug ; ns2:description "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. [PubChem]"@en ; ns2:dosage , , , , , , ; ns2:generalReferences "# Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C: Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9885371 # Herben VM, ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996 Aug;31(2):85-102. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8853931 # Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ: An overview of the clinical pharmacology of topotecan. Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-12-S5-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9122737"@en ; ns2:group "investigational"@en , "approved"@en ; ns2:halfLife "2-3 hours"@en ; ns2:indication "For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy."@en . @prefix owl: . @prefix ns4: . ns1:DB01030 owl:sameAs ns4:DB01030 . @prefix ns5: . ns1:DB01030 owl:sameAs ns5:DB01030 . @prefix dcterms: . ns1:DB01030 dcterms:title "Topotecan"@en . @prefix adms: . @prefix ns8: . ns1:DB01030 adms:identifier ns8:DB01030 , . @prefix ns9: . ns1:DB01030 adms:identifier ns9:TTC . @prefix ns10: . ns1:DB01030 adms:identifier ns10:PA451729 . @prefix ns11: . ns1:DB01030 adms:identifier ns11:C11158 , . @prefix ns12: . ns1:DB01030 adms:identifier ns12:Topotecan , , ; ns2:mechanismOfAction "Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death). Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (\u22121) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme\u2013substrate complex, Topotecan acts as an uncompetitive inhibitor."@en ; ns2:packager , ; ns2:patent , , , ; ns2:routeOfElimination "Renal clearance is an important determinant of topotecan elimination. In a mass balance/excretion study in 4 patients with solid tumors, the overall recovery of total topotecan and its N-desmethyl metabolite in urine and feces over 9 days averaged 73.4 \u00B1 2.3% of the administered IV dose. Fecal elimination of total topotecan accounted for 9 \u00B1 3.6% while fecal elimination of N-desmethyl topotecan was 1.7 \u00B1 0.6%."@en ; ns2:synonym "Topotecane"@en , "Topotecanum"@en , "9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin"@en ; ns2:toxicity "The primary anticipated complication of overdosage would consist of bone marrow suppression."@en . @prefix ns13: . ns1:DB01030 ns13:hasAHFSCode ; ns2:proteinBinding "35%"@en ; ns2:salt " "@en ; ns2:synthesisReference "Venkata Raghavendra Palle, Sekhar Nariyam, Lankeshwara Matti, \"PROCESS FOR PREPARING TOPOTECAN.\" U.S. Patent US20070149783, issued June 28, 2007."@en . @prefix ns14: . @prefix ns15: . ns1:DB01030 ns14:hasConcept ns15:M0029340 . @prefix foaf: . ns1:DB01030 foaf:page , ; ns2:IUPAC-Name ; ns2:InChI ; ns2:Molecular-Formula ; ns2:Molecular-Weight ; ns2:Monoisotopic-Weight ; ns2:SMILES ; ns2:Water-Solubility , ; ns2:logP , , ; ns2:logS . @prefix ns17: . ns1:DB01030 ns13:hasATCCode ns17:L01XX17 ; ns2:H-Bond-Acceptor-Count ; ns2:H-Bond-Donor-Count ; ns2:InChIKey ; ns2:Polar-Surface-Area--PSA- ; ns2:Polarizability ; ns2:Refractivity ; ns2:Rotatable-Bond-Count ; ns2:affectedOrganism "Humans and other mammals"@en ; ns2:casRegistryNumber "119413-54-6"@en ; ns2:category " "@en ; ns2:containedIn , , ; ns2:Bioavailability ; ns2:Ghose-Filter ; ns2:MDDR-Like-Rule ; ns2:Melting-Point ; ns2:Number-of-Rings ; ns2:Physiological-Charge ; ns2:Rule-of-Five ; ns2:Traditional-IUPAC-Name ; ns2:pKa--strongest-acidic- ; ns2:pKa--strongest-basic- .